Guangzhou Kingmed Diagnostics Group (603882.SH) plans to invest in the establishment of Jinkun Medical Intelligence to expand its comprehensive solutions business for digitalizing healthcare.

Guangzhou Kingmed Diagnostics Group (603882.SH) announced that the company plans to use its own funds to jointly invest with Guangzhou Shengyu Fang Investment Consulting Partnership Enterprise (Limited Partnership) and other companies to establish Guangzhou Jinkun Medical Intelligence Technology Co., Ltd. (referred to as "Jinkun Medical Intelligence") with a registered capital of 50 million yuan. The company will subscribe for 10 million yuan, holding a 20% stake. Jinkun Medical Intelligence's core business will focus on "smart healthcare", based on in-depth insights into the entire medical scene, integrating self-developed AI products and ecological partner resources, to provide comprehensive medical digitalization solutions and end-to-end digitalization services for diverse customers such as hospitals, pharmaceutical companies, insurance, and IVD manufacturers. The positioning of Jinkun Medical Intelligence's business complements and synergizes with the company's main business, which will help expand the company's strategic layout in the field of smart healthcare.